Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population

NCT00450905 | Terminated Phase 3 DMC

• 1 other identifier: F06001
• Study Type: interventional
• Target: 200
• Locations: 2 countries
• Sites: 21

Brief Summary

This study is being performed to determine the safety and efficacy of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain associated with Fibromyalgia.

Conditions

Fibromyalgia; Pain

Keywords

Chronic musculoskeletal pain secondary to Fibromyalgia

Outcome Measures

Primary Outcomes (1)

• Clinically significant pain reduction, evidenced by a statistically significant difference between active and placebo groups in percentage of subjects who achieve a pain reduction of at least 30% at week 12 as compared to the Baseline.

Secondary Outcomes (1)

• Additional outcome measures will include mood alteration, sleep quality, improvement of physical functioning and relief medication usage by subjects in both groups.

Interventions

PRIMA Device DEVICE

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of chronic musculoskeletal pain of at least six months duration secondary to FMS using American College of Rheumatology (ACR) criteria and with the minimum of 11 of 18 defined tender points, measured by dolorimeter at a threshold of up to 4 kg of pressure
• Males and females, 18 years and older
• Able to complete assessment index forms unaided by caregiver/interpreter
• Pain score of 4 or greater on the Numerical Rating Scale (NRS), averaged from the Baseline Period scores recorded on the 7 days immediately prior to randomization
• Demonstration of stabilized pain scores as measured on the NRS during the Baseline Period (Days -7 to -1)
• Able to tolerate prohibition of all medications for pain, depression and sleep disorders except for acetaminophen (up to 4 g/day) and cardiac aspirin (up to 325 mg/day) demonstrated for the Stabilization and Baseline Periods prior to randomization
• Able and willing to provide a written informed consent

You may not qualify if:

• Unwilling or unable to sign an informed consent, or to comply with the protocol
• Evidence of inflammatory rheumatic disease, secondary fibromyalgia, or other severe painful disorders that might confound assessment of FMS pain
• Currently under treatment (pharmacological or cognitive therapy) for a Major Depressive Episode (MDE) or has demonstrated suicidal ideation in the past
• History or current treatment of migraine, tension or cluster headache requiring regular medication
• History or current treatment of seizure disorder
• History or current treatment of cancer with the exception of basal cell carcinoma and cervical dysplasia
• Cognitive dysfunction or personality disorder which would preclude self-directed treatment, self assessment and / or diary completion
• Clinically significant or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise participation
• Hearing aids, metal implants (excludes dental work) above mid torso or in the cranium (e.g. plates, implants or clips). (Metal implants in parts of the body below mid-torso, such as knee or hips replacements, clips, screws or plates to stabilize fractures are acceptable)
• Pacemakers, defibrillators, implanted neurostimulators, implanted drug pumps or other electrical implanted devices
• Insufficient knowledge of English to complete the self-assessment forms
• History of or current drug or alcohol abuse
• History of abuse of a previous physician relationship or the medical system
• Receiving disability insurance, applying for disability insurance, or engaged in litigation related to FMS
• Use of an investigational drug or device in a controlled study within 30 days

Sponsors & Collaborators

• Fralex Therapeutics: lead
• PharmaNet: collaborator
• McDougall Scientific Limited: collaborator

Study Sites (21)

Unknown Facility

Encinitas, California, 92024, United States

Location

Unknown Facility

Garden Grove, California, 92845, United States

Location

Unknown Facility

La Jolla, California, 92037, United States

Location

Unknown Facility

Lancaster, California, 93534, United States

Location

Unknown Facility

Murrieta, California, 92563, United States

Location

Unknown Facility

Palmdale, California, 93550, United States

Location

Unknown Facility

Gainsville, Florida, 32610, United States

Location

Unknown Facility

West Palm Beach, Florida, 33409, United States

Location

Unknown Facility

Winter Park, Florida, 32789, United States

Location

Unknown Facility

Lexington, Kentucky, 40503, United States

Location

Unknown Facility

Rochester, Minnesota, 55905, United States

Location

Unknown Facility

New York, New York, 10003, United States

Location

Unknown Facility

Rochester, New York, 14642-8604, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27103, United States

Location

Unknown Facility

Altoona, Pennsylvania, 16602, United States

Location

Unknown Facility

Seattle, Washington, 98104, United States

Location

Unknown Facility

Spokane, Washington, 99216, United States

Location

Unknown Facility

Hamilton, Ontario, L8N 3Z5, Canada

Location

Unknown Facility

Ottawa, Ontario, K1H 1A2, Canada

Location

Unknown Facility

Toronto, Ontario, M2N 6K7, Canada

Location

Unknown Facility

Toronto, Ontario, M9W 4L6, Canada

Location

MeSH Terms

Conditions

Fibromyalgia; Pain

Condition Hierarchy (Ancestors)

Muscular Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Neuromuscular Diseases; Nervous System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: March 21, 2007
• First Posted: March 22, 2007
• Study Start: March 1, 2007
• Study Completion: December 1, 2008
• Last Updated: October 6, 2008

Record last verified: 2008-02

Locations

CA (4); US (17)